TY - JOUR T1 - Perindopril plus indapamide reduced death and major macrovascular and microvascular events in type 2 diabetes JF - Evidence Based Medicine JO - Evid Based Med SP - 49 LP - 49 DO - 10.1136/ebm.13.2.49 VL - 13 IS - 2 A2 - , Y1 - 2008/04/01 UR - http://ebm.bmj.com/content/13/2/49.abstract N2 - A PatelDr A Patel, University of Sydney, Sydney, New South Wales, Australia; apatel@george.org.auDesign:randomised controlled trial (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation [ADVANCE]).Allocation:concealed.*Blinding:blinded (outcome assessors, {patients, clinicians, data collectors, data analysts, and manuscript writers}).*†Setting:215 centres in 20 countries in Asia, Australasia, Europe, and North America.Patients:11 140 patients ⩾55 years of age (mean age 66 y, 57% men) who were diagnosed with type 2 diabetes mellitus at ⩾30 years of age and had ⩾1 of the following: history of major cardiovascular disease or risk factor for cardiovascular disease (ie, history of major microvascular disease, current cigarette smoking, total cholesterol >6.0 mmol/l, high-density lipoprotein cholesterol <1.0 mmol/l, urinary albumin-creatinine ratio 30–300 μg/mg, diagnosis of type 2 diabetes ⩾10 years previously, or age ⩾65 y). Exclusion criteria included definite indication for an angiotensin-converting enzyme inhibitor other … ER -